Ischaemic heart disease

PCSK9 inhibitor no risk for diabetes

The use of PCSK9 inhibitor alirocumab for LDL-cholesterol lowering in post-ACS patients does not appear to have any adverse glucometabolic effect on people regardless of glycaemic status. Speaking at the 2018 ADA Scientific Sessions in Orlando, cardiologist Professor Kausik Ray said the pre-specified analyses of the ODYSSEY Outcomes study showed no signal for new onset ...

Already a member?

Login to keep reading.

© 2021 the limbic